U.S. markets open in 3 hours

AVITA Medical, Inc. (RCEL)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
21.86+0.31 (+1.44%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Previous Close21.55
Open21.67
Bid0.00 x 800
Ask0.00 x 1400
Day's Range21.53 - 22.10
52 Week Range16.87 - 30.95
Volume152,680
Avg. Volume140,012
Market Cap543.066M
Beta (5Y Monthly)0.34
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMay 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est40.20
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • AVITA Medical Announces Preliminary Fourth Quarter 2021 Financial Results
    GlobeNewswire

    AVITA Medical Announces Preliminary Fourth Quarter 2021 Financial Results

    VALENCIA, Calif. and MELBOURNE, Australia, June 15, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today announced preliminary, unaudited financial results for the fiscal fourth quarter 2021. For the fiscal quarter ending June 30, 2021, AVITA Medical has to date realized total revenue in excess of its

  • U.S. Food and Drug Administration Approves Expanded Use of the RECELL® System for the Treatment of Extensive Burns and Pediatric Patients
    GlobeNewswire

    U.S. Food and Drug Administration Approves Expanded Use of the RECELL® System for the Treatment of Extensive Burns and Pediatric Patients

    Expanded indication for use includes RECELL System for treatment of full-thickness acute burn wounds of all sizes in pediatric and adult patientsVALENCIA, Calif. and MELBOURNE, Australia, June 10, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today announced that the U.S. Food and Drug Administration

  • AVITA Medical, Inc. Appoints Two New Non-Executive Members to the Board of Directors
    GlobeNewswire

    AVITA Medical, Inc. Appoints Two New Non-Executive Members to the Board of Directors

    VALENCIA, Calif. and MELBOURNE, Australia, June 01, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (Nasdaq: RCEL; ASX: AVH) (“AVITA Medical”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today the appointment of James Corbett and Jan Stern Reed to its Board of Directors effective July 1, 2021. Mr. Corbett has approximately 40 years of leadership experience in